PAOG Entertains Partnership To Accelerate Development Of CBD Pharmaceutical Treatment For $14 Billion COPD Market
PAO Group, Inc. (OTC Pink: PAOG) announced it is seeking partnerships to enhance its RespRx CBD pharmaceutical for Chronic Obstructive Pulmonary Disease (COPD). The COPD treatment market is projected to grow from $9 billion in 2015 to $14.1 billion by 2025. PAOG recently acquired intellectual property related to CBD extraction (U.S. Patent No. 9,199,960) and is collaborating with Veristat to prepare an IND for FDA approval. The company has seen effectiveness in its trials for COPD and received inquiries regarding its RespRx developments, indicating strong market interest.
- Seeking partnerships to accelerate RespRx development.
- Acquired valuable intellectual property (U.S. Patent No. 9,199,960).
- COPD market projected to grow to $14.1 billion by 2025.
- Engaged Veristat as a CRO to prepare an IND for FDA.
- None.
Sandusky, OH, Oct. 28, 2021 (GLOBE NEWSWIRE) -- PAO Group, Inc. (OTC Pink: PAOG) today announced the company is entertaining a partnership opportunity to accelerate the ongoing development of its RespRx CBD pharmaceutical for the treatment of Chronic Obstructive Pulmonary Disease (COPD).
The COPD treatment market is anticipated to rise from an estimated
Last year, PAOG acquired intellectual property derived through research into CBD extracted in association with a patented extraction method (U.S. Patent No. 9,199,960). The ongoing research targets the treatment of respiratory disorders in support of a pharmaceutical being developed by PAOG under the name RespRx.
PAOG has engaged Veristat as a CRO to prepare an IND for the FDA.
PAOG’s RespRx research has shown effectiveness in the treatment of Chronic Obstructive Pulmonary Disease (COPD) and other similar respiratory conditions.
The British Medical Journal (BMJ) recently released a report on a case study where CBD demonstrated effectiveness in the treatment of lung cancer and COPD.
RespRx, in addition to its clinical research with COPD, has been engaged in select, non-clinical trials to treat cancer and demonstrated effectiveness.
PAOG has received numerous inquiries into its RespRx developments. Now PAOG is considering a partnership opportunity with a larger organization that has the potential to accelerate the ongoing development of RespRx.
PAOG will release more information as the partnership opportunity develops.
Learn more about PAOG at www.paogroupinc.com.
Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.
CONTACT INFORMATION
Contact Us:
Jim DiPrima
888-272-6472
info@pao.group
FAQ
What is the latest announcement from PAO Group regarding its COPD treatment?
What is the projected market size for COPD treatments by 2025?
Who is PAO Group working with for FDA approval of RespRx?
What recent research supports the effectiveness of RespRx for COPD?
What significant patent did PAO Group acquire related to CBD?
